STMN1 and ovarian cancer: Collectively, these mechanistic observations establish STMN1 as a key determinant of ovarian cancer cell responsiveness to PTX, while further validating our co-delivery system as a rational, targeted therapeutic strategy to surmount PTX chemoresistance in ovarian cancer—addressing a critical unmet need in clinical management of this disease.